53 results about "Levosimendan" patented technology

The invention relates to a pharmaceutical composition, wherein each unit dosage comprises: (1) 5-50mg of Levosimendan or its pharmaceutically acceptable salt, (2) 10-200mg of Solutol HS 15, (3) 0.1-1000ml of medicinal solvent.

Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and / or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.

The invention provides a levosimendan-containing injection medicine preparation and a preparation method thereof, and belongs to the field of medicine preparations. The preparation can be injection solution or freeze-dried powder and is mainly used for administrating medicines by injection. The injection solution comprises levosimendan serving as an active component or medicinal derivative of thelevosimendan and sulfobutyl beta cyclodextrin serving as a solubilizing stabilizer or medicinal salt of the sulfobutyl beta cyclodextrin, the weight ratio of the active component to the solubilizing stabilizer is 1:10-300, preferably, the weight ratio is 1:40-100, and most preferably, the weight ratio is 1:64-100. According to the preparation, the accessory sulfobutyl beta cyclodextrin has betterwater solubility, less hemolytic action and low renal toxicity as compared with hydroxypropyl beta cyclodextrin and is firstly used as a clathration material of the levosimendan or the medicinal derivative of the levosimendan. Compared with marketed similar injection solution, the injection solution takes water as a solvent, does not contain ethyl alcohol and is better in safety, and a freeze-dried preparation is more stable and easily stored at the room temperature.

The invention provides a synthesis process of levosimendan. The process includes: taking acetanilide and 2-chloropropionylchloride as the starting materials, conducting Friedel-Crafts acylation to obtain N-[4-(2-chloropropionylchloride)phenyl]acetamide (compound 1), then synthesizing 6-(4-aminophenyl)-5-methyl-4, 5-dihydropyridazine-3(2H)-one (compound 2) by one-pot method, and further condensing the compound 2 with malononitrile to obtain levosimendan (compound 3). The process provided by the invention has the characteristics of few step, simple operation, easy separation and purification of product, high yield and low cost, and employs common chemical materials as the reagents, thus being a new process suitable for industrial production.

The invention provides medicine production equipment capable of improving yield. The medicine production equipment comprises a stirring device, a material adding device, a vacuum drying device and a control device, wherein a plurality of flow guide pipelines are arranged between the material adding device and the stirring device. With the adoption of the equipment, a stirring process during the production of levosimendan is controlled through a singlechip microcomputer, materials are automatically added into the stirring device according to input preset stirring time, stirring speed and the desired temperature during stirring, and are stirred according to the required stirring time at the corresponding stirring speed under the preset temperature value, the temperature and the pH inside the stirring device are monitored so that the temperature and the pH are within the preset range, the highest yield is achieved, and finally the production efficiency of levosimendan is improved.

The invention relates to intermittent administration of an inotropic agent (such as, but not limited to a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders, such as, pulmonary hypertension, myocardial ischemia, acute heart failure, chronic heart failure or acute on chronic heart failure.

The invention relates to peroral pharmaceutical compositions which release levosimendan in a controlled fashion with reduced occurrence of undesired effects. Levosimendan, or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile, is useful in the treatment of congestive heart failure.

The present invention relates to one kind of heart failure resisting medicine, cyclodextrin or its derivative included preparation of levosimendan. The preparation has calcium-sensitive positive muscle medicine levosimendan as main component, and beta-cyclodextrin or its derivative, such as hydroxypropyl beta-cyclodextrin as including matter.

A method for the prevention of thrombotic, embolic and / or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.

The invention relates to a stable levosimendan medicine composition. The medicine composition consists of two chambers, wherein a medicine chamber is filled with the levosimendan or a pharmaceutically acceptable salt thereof; and a solvent chamber is filled with a pharmaceutically usable solvent. The solvent contains a pharmaceutically acceptable organic solvent and solubilizing agent, and also can be added with a pharmaceutically acceptable acid. The composition can be used for intravenous injection, or taken orally. The invention also relates to a method for preparing the composition.

The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan is present in a solubilized form. The formulations have therapeutically and commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solution after reconstitution in water or an aqueous solvent. Levosimendan or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.

The invention discloses a pharmaceutical composition of levosimendan sodium for acute decompensated heart failure symptoms and a preparation method. The preparation of the invention can be an injection or a dry powder, and the dry powder is reconstituted to form an original solution. Mainly used for administration by injection route, the pharmaceutical composition of the present invention comprises: levosimendan sodium as an active ingredient, and excipients. The invention solves the problems of insolubility of levosimendan free base in water and instability of impurities degraded by hydrolysis during marketing and storage, so that levosimendan sodium can be prepared into a stable injection with water as a solvent.

A combination therapy for promoting diuresis in a patient comprises administering levosimendan or its active metabolite or any of their pharmaceutically acceptable salts in conjunction with a diuretic to a patient. The combination therapy provides diuretic effect also in patients who are refractory to standard diuretic therapy.